
-
Australian champion cyclist Dennis gets suspended sentence after wife's road death
-
Protection racket? Asian semiconductor giants fear looming tariffs
-
S. Korea Starbucks in a froth over presidential candidates names
-
NATO hatches deal on higher spending to keep Trump happy
-
Eurovision stage a dynamic 3D 'playground': producer
-
Cruise unleashes 'Mission: Impossible' juggernaut at Cannes
-
Suaalii in race to be fit for Lions Tests after fracturing jaw
-
Pacers oust top-seeded Cavs, Nuggets on brink
-
Sony girds for US tariffs after record annual net profit
-
China, US slash sweeping tariffs in trade war climbdown
-
Human Rights Watch warns of migrant worker deaths in 2034 World Cup host Saudi Arabia
-
Sony logs 18% annual net profit jump, forecast cautious
-
China, US to lift sweeping tariffs in trade war climbdown
-
Asian markets swing as China-US trade euphoria fades
-
Australian seaweed farm tackles burps to help climate
-
Judgment day in EU chief's Covid vaccine texts case
-
Trump set to meet Syrian leader ahead of Qatar visit
-
Misinformation clouds Sean Combs's sex trafficking trial
-
'Panic and paralysis': US firms fret despite China tariff reprieve
-
Menendez brothers resentenced, parole now possible
-
'Humiliated': Combs's ex Cassie gives searing testimony of abuse
-
Latin America mourns world's 'poorest president' Mujica, dead at 89
-
Masters champion McIlroy to headline Australian Open
-
Coca-Cola Europacific Partners plc Announces Capital Markets Event
-
Hemogenyx Pharmaceuticals PLC Announces Pediatric Amendment to Clinical Protocol
-
Sean Combs's ex Cassie says he coerced her into 'disgusting' sex ordeals
-
McIlroy, Scheffler and Schauffele together for rainy PGA battle
-
Uruguay's Mujica, world's 'poorest president,' dies aged 89
-
Lift-off at Eurovision as first qualifiers revealed
-
Forest striker Awoniyi placed in induced coma after surgery: reports
-
'Kramer vs Kramer' director Robert Benton dies: representative
-
Tatum suffered ruptured right Achilles in playoff defeat: Celtics
-
US stocks mostly rise on better inflation data while dollar retreats
-
Winning farewell for Orlando Pirates' Spanish coach Riveiro
-
Lift-off at Eurovision as first semi-final takes flight
-
UN relief chief urges action 'to prevent genocide' in Gaza
-
Baseball pariahs Rose, Jackson eligible for Hall of Fame after league ruling
-
Scheffler excited for 1-2-3 group with McIlroy, Schauffele
-
Sean Combs's ex Cassie says he forced her into 'disgusting' sex ordeals
-
Uruguay's 'poorest president' Mujica dies aged 89
-
Senior UN official urges action 'to prevent genocide' in Gaza
-
'Kramer vs Kramer' director Robert Benton dies: report
-
Sinner moves through gears to reach Italian Open quarters
-
Massages, chefs and trainers: Airbnb adds in-home services
-
Republicans eye key votes on Trump tax cuts mega-bill
-
Brazil legend Marta returns for Japan friendlies
-
McIlroy, Scheffler and Schauffele together to start PGA
-
Jose Mujica: Uruguay's tractor-driving leftist icon
-
Uruguay's ex-president Mujica dead at 89
-
It's showtime at Eurovision as semis begin

Drew Weissman, Nobel-winning mRNA pioneer
Drew Weissman's decades of research into mRNA technology paved the way for Covid-19 vaccines, finally earning a Nobel prize for the physician-scientist.
The 64-year-old University of Pennsylvania immunologist, who won the Nobel Medicine Prize along with long-time collaborator Katalin Kariko on Monday, is far from done.
His next quests include, among others, developing a vaccine against all future coronaviruses.
"There have been three (coronavirus) pandemics or epidemics in the past 20 years," Weissman told AFP recently, referring to the original SARS virus, MERS and Covid-19.
"You have to assume there's going to be more, and our idea was that we could wait for the next coronavirus epidemic or pandemic, and then spend a year and a half making a vaccine. Or we could make one now."
- Twin breakthroughs-
The world is now aware of the elegance of the mRNA (messenger ribonucleic acid) vaccines, that deliver genetic instructions to cells telling them to recreate the spike protein of the coronavirus, in order to trigger effective antibodies when they encounter the real thing.
But back when Weissman teamed up with Kariko in the 1990s, the research was considered a scientific dead-end, and working with DNA was considered a more promising avenue.
"We started working together in 1998, and that was without much funding and without much in the way of publications," he said.
In 2005, the pair found a way to alter synthetic RNA to stop it from causing a massive inflammatory response found in animal experiments.
"Just before our paper was published, I said 'Our phones are going to ring off the hook,'" he recalls.
"We sat there staring at our phones for five years, and they never rang!"
With a second big breakthrough in 2015, they found a new way to deliver the particles safely and effectively to their target cells, using a fatty coating called "lipid nanoparticles."
Both developments are part of the Pfizer and Moderna Covid-19 vaccines today.
- Helping people -
Weissman grew up in Lexington, Massachusetts.
His father and mother, both since retired, were an engineer and dental hygienist, respectively.
"When I was five years old, I was diagnosed as a type-one diabetic, and back then it was testing urine and taking insulin shots a few times a day," he recalled, and this motivated him to pursue science.
He was educated at Brandeis University and completed an MD-Phd program in immunology at Boston University.
As a young fellow at the National Institutes of Health, he worked for several years in Anthony Fauci's lab on HIV research, before finally arriving at his long-time home Penn.
Weissman was a practicing doctor until a few years ago, and says it brings him great joy that his invention has helped save millions of lives.
"I'm a clinician scientist, my dream since starting college and medical school was to make something that helps people. I think I can say that I've done that. So I am incredibly happy," he said.
Beyond vaccines, mRNA technology is also being heralded for its potential across medicine.
Weissman's team is working on using RNA to develop a single-injection gene therapy to overcome the defect that causes sickle cell anemia, a genetic blood disease that 200,000 babies are born with in Africa every year.
Significant technical challenges remain to ensure the treatment is able to correctly edit genes and is safe, but the researchers are hopeful.
Bone marrow transplant, an expensive treatment with serious risks, is currently the only cure.
O.Johnson--AMWN